Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia

VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia.

VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.

Inclusion Criteria:

• Refractory hypercholesterolemia
• Refractory hypertriglyceridemia

Exclusion Criteria:

• Active or history of chronic liver disease
• Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
• Clinically significant or abnormal laboratory values as defined by the protocol